UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade

UroGen Pharma Ltd. (NASDAQ:URGN) shares saw unusually-strong trading volume on Monday after HC Wainwright upgraded the stock from a neutral rating to a buy rating. HC Wainwright now has a $50.00 price target on the stock. Approximately 2,166,518 shares were traded during trading, an increase of 119% from the previous session’s volume of 989,570 shares.The stock last traded at $14.28 and had previously closed at $12.03.

Other analysts also recently issued research reports about the company. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Thursday, June 12th. The Goldman Sachs Group dropped their price objective on UroGen Pharma from $16.00 to $3.00 and set a “neutral” rating on the stock in a research note on Thursday, May 22nd. Guggenheim reaffirmed a “buy” rating and set a $30.00 price objective (up previously from $15.00) on shares of UroGen Pharma in a research note on Friday. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research note on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective on the stock. Finally, Oppenheimer dropped their price objective on UroGen Pharma from $36.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 3rd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $32.86.

Insider Transactions at UroGen Pharma

In other UroGen Pharma news, insider Mark Schoenberg sold 5,162 shares of the company’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the sale, the insider now owns 153,378 shares in the company, valued at $1,130,395.86. This represents a 3.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 5.10% of the company’s stock.

Institutional Trading of UroGen Pharma

Large investors have recently made changes to their positions in the company. CWM LLC grew its position in shares of UroGen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock worth $58,000 after acquiring an additional 5,140 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in UroGen Pharma during the 4th quarter worth $59,000. Lazard Asset Management LLC acquired a new position in UroGen Pharma during the 4th quarter worth $67,000. GAMMA Investing LLC lifted its holdings in shares of UroGen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock valued at $83,000 after purchasing an additional 7,392 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new position in shares of UroGen Pharma in the fourth quarter worth about $101,000. 91.29% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Price Performance

The stock has a 50 day simple moving average of $8.63 and a two-hundred day simple moving average of $10.05. The company has a market cap of $661.17 million, a price-to-earnings ratio of -4.55 and a beta of 0.40. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. On average, equities research analysts predict that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.